PI Update for Pradaxa® (dabigatran etexilate) | BI US
Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
Search
Patient Assistance Program
BI Cares Patient Assistance Program Error
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
Newsletter Duplicate subscription error
Newsletter Duplicate subscription error
Animal Health: Our Responsibility
BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
Our Responsibility
Our Responsibility
Mental Disorders
Mental Disorders
Lung Diseases
Our Therapeutic Areas
Cancer
Cancer
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Biosimilar Candidate to Humira® Accepted For Review | BI US
Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Respiratory
Respiratory
Edda Dankmeyer
Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Cardio-Renal-Metabolic diseases
Cardio-Renal-Metabolic diseases
Mental Health disorders
Mental Health disorders
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Research Beyond Borders
Research Beyond Borders
Immunology
Immunology
Oncology Partnering Interests | Boehringer Ingelheim US
Click here to view our range of downloads on Boehringer Ingelheim's oncology & cancer immunology partnering interests.
Our Retinal Health Partnering Interests
Our Retinal Health Partnering Interests
Partnering Interests in CardioMetabolic Diseases
Partnering Interests in CardioMetabolic Diseases
Delving into Diabetic Retinopathy
Delving into Diabetic Retinopathy